Ecolab Inc (NYSE:ECL) stock fell 0.082% (As on July 9, 11:20:19 AM UTC-4, Source: Google Finance) after Stifel has raised its investment rating on the company stock from Hold to Buy, setting a new price target of $283, up from the previous $233.
The firm believes that Ecolab’s prospects are more favorable than they have been for many years, anticipating a sustained positive trajectory. The optimism is based on expectations that the company will meet its 20% EBIT margin goal in the coming years, supported by various contributing factors. Stifel’s new price target is based on a 32x P/E multiple applied to the anticipated 2026 earnings per share (EPS) of $8.83. This target represents the firm’s forecast for Ecolab’s financial performance and market valuation in the next several years. The analyst highlighted that Ecolab’s operational improvement and margin expansion narrative should capture investors’ interest. The expectation is that the company’s financial figures will likely see upward revisions in the future. Stifel’s positive outlook on Ecolab is rooted in the company’s high-quality standing and the potential for increased estimates moving forward. The firm’s analysis suggests that Ecolab is positioned for continued success and recommends that investors consider adding the stock to their portfolios.
On the other hand, the company has recently announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Purolite’s DurA Cycle, a protein A chromatography resin for large-scale purification processes. This new affinity resin is being introduced at the BIO International Convention (BIO 2024), being held June 3-6 in San Diego. This latest innovation marks a significant milestone in Purolite’s long-term strategic partnership with Repligen, further solidifying Ecolab’s dedication to driving advancements in the bioprocessing industry.
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies, where cost of goods is critical for biologic drug developers. This new resin represents the latest addition to Purolite’s toolbox, following two new resins launched in the last eighteen months to address purification challenges associated with ever-increasingly complex drugs. The announcement of Purolite’s latest resin follows news of its investment in a new bioprocessing production facility based in Landenberg, PA, which complements its UK-based facility, providing dual continent manufacturing capabilities to address growing customer demand.
Additionally, the company has increased full year 2024 adjusted diluted earnings per share range to $6.40 – $6.70, +23% – 29%, from prior $6.10 – $6.50 range.